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Abstract
Background Chronic obstructive pulmonary disease
(COPD) is a leading cause of morbidity and mortality
worldwide. COPD is characterized by poor treatment
adherence, and patient medication preferences may con-
tribute to adherence.
Methods A discrete choice experiment with an internet
panel drawn from the USA was used to evaluate preference
and willingness to pay (WTP) of COPD patients for long-
acting maintenance medications. Key attributes derived
from earlier qualitative research (brief literature review and
focus groups) with COPD patients on maintenance therapy
included symptom relief, speed of feeling medication start
to work, inhaler ease of use, rescue medication use, side
effects, and monthly out-of-pocket co-pay. Patients were
presented with hypothetical medications with different
profiles and asked which they preferred. Utilities and
marginal WTP in monthly co-pay dollars were estimated
for all patients and by severity.
Results Utilities for 515 participants were in the expected
direction and highest for the most favorable attribute lev-
els. Each attribute evaluated was important, and partici-
pants were willing to pay a premium to obtain each benefit.
On average, WTP was as high as $US64 for complete
symptom relief, $US59 for no side effects, $US32 to rarely
use rescue medication, $US16 for a quick and easy to use
inhaler, and $US13 for feeling medication work quickly
(within 5 min; average WTP $US18/month for patients
with severe/very severe COPD).
Conclusion As expected, efficacy and safety were most
valued by patients; however, this study showed that other
COPD medication attributes, such as rescue medication,
ease of use, and feeling medication work quickly, are also
important in patient preferences.
Key Points for Decision Makers
There are multiple attributes of a chronic obstructive
pulmonary disease (COPD) maintenance therapy that
patients may take into consideration in evaluating a
medication.
In a US sample, COPD medication attributes of
efficacy and safety were highly valued by patients,
but other attributes, such as rescue medication, ease
of use, and feeling medication work quickly, are also
important in patient preferences.
Patients are willing to pay more for a medication
with attractive characteristics.
1 Introduction
Chronic obstructive pulmonary disease (COPD) is one of
the leading causes of morbidity and mortality, with an
estimated prevalence of 80 million people with moderate to
severe COPD worldwide [1], and is predicted to become
the third leading cause of death worldwide by 2030 [1, 2].
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The three main symptoms of COPD are shortness of breath
(dyspnea), cough, and excessive sputum production. COPD
treatments focus on symptom alleviation, reduction of
exacerbations, maintenance of good lung function, and
improving health-related quality of life. Optimal manage-
ment of COPD is complex, requiring behavioral and life-
style changes from patients, including quitting smoking
and adherence to prescribed medication. Pharmacological
treatment for most patients includes prescription mainte-
nance medication (taken on a regular daily schedule) and
quick-acting ‘rescue’ medication (taken during acute
symptoms) [3].
Despite the prevalence of this condition and the existence
of clinical guidelines to manage COPD [3–5], treatment
adherence remains poor, with recent estimates indicating
that, on average, 60 % of patients with COPD are noncom-
pliant with prescribed therapy [6]. COPD patients using
multiple long-acting maintenance inhalers (two or more
prescriptions) have also been shown to be less adherent and
have higher discontinuation rates than single-inhaler users
[7]. Improving compliance among this patient population is
particularly important, as poor adherence to drug therapy has
been identified as the major factor resulting in emergency
hospitalization among COPD patients [8–10]. Conversely,
better medication adherence has been associated with both a
decrease in the number of hospitalizations and length of
hospital stay among patients with chronic respiratory ail-
ments [11]. Patient beliefs, experiences, and behaviors with
regard to COPD and its treatment have been shown to be
powerful predictors of medication adherence [12], which
highlights the importance of including the patient perspec-
tive in COPD medication and management.
Although multiple factors may drive patient preference
and subsequent medication adherence, a key step to
improving compliance is to understand patients’ perspec-
tives regarding favored attributes of their COPD medica-
tion. Attributes important to patients can include, but are
not limited to, aspects such as efficacy, cost, ease of use,
speed of onset, and side effects. To date, research on COPD
patient preferences has focused on ease of use and con-
venience of different modes of administration (i.e., inhaler
devices, nebulizers) [13–18]. Previous work among asthma
patients has shown that they prefer a drug that they can feel
working right away [19]. Patient preferences for medica-
tion attributes may play a role in the decision of COPD
patients to take medications as directed [6], and under-
standing these preferences may help to improve patient
adherence to treatment regimens.
1.1 Study Overview
The purpose of this study was twofold—first, to identify
attributes that patients consider integral in a COPD
maintenance medication and, second, to understand the
relative value of each of these attributes as it relates to
overall patient preference for a maintenance medication.
The study was performed in two phases: initially, qualita-
tive research was conducted to inform the types of COPD
medication attributes that are important to patients and,
subsequently, a discrete choice experiment (DCE) study
was implemented to quantitatively evaluate patient pref-
erences for each of the attributes. Each phase of this study
was approved by the appropriate institutional review
boards and all participants provided informed consent
before the initiation of data collection procedures.
2 Methods
2.1 Focus Group Phase
In phase I, qualitative research was conducted to identify
key medication attributes in COPD and the degrees (or
levels) of each attribute that were important to patients.
A brief, targeted review of recent literature was first
conducted to identify potential attributes (or characteris-
tics) of COPD medications that had salience for patients.
Searches were conducted using the PubMed database,
examining articles in English, published between 2000
and 2008. Appropriate articles were identified pertaining
to treatment characteristics by using a search strategy
that included descriptors related to COPD, patient satis-
faction/preference, medication/treatment, and treatment
effects or outcomes. The key concepts identified in the
brief literature review informed potential areas of dis-
cussion in patient focus groups. The focus group dis-
cussions served to confirm treatment concepts reflected
in the recent literature, identify any additional concepts
that should be included, and further refine understanding
of attributes relevant to treatment from the patient
perspective.
Two focus group sessions of six to seven patients
each were conducted in March 2009 at a pulmonary
clinic in the USA. Participants were at least 40 years
old, with a clinical diagnosis of moderate to very severe
COPD and dyspnea, and receiving a long-acting COPD
maintenance therapy at the time of the focus group.
There were no exclusion criteria with regard to use of
short-acting/rescue medications. A semi-structured focus
group discussion guide was used to facilitate these
conversations, and sessions were led by a trained mod-
erator with research experience in COPD. The discussion
guide was designed to elicit spontaneous feedback from
patients about COPD symptoms experienced on a typical
day, impact of symptoms, and their experiences with
COPD long-acting or maintenance medications.
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2.2 Discrete Choice Experiment (DCE) Study Phase
In phase II, a quantitative study using DCE methodology
was designed based on the qualitative findings obtained in
phase I. DCE is a type of conjoint analysis [20–24], and
can be used to estimate willingness to pay (WTP) for
healthcare interventions [25, 26]. The method allows
respondents to choose their preferred option between
hypothetical scenarios designed to reflect the different
attributes that real world decisions would contain, and
allow them to make ‘trade-offs’ between these attributes to
reveal their preferences.
The DCE study was conducted in August 2009 among
US patients with COPD on maintenance therapy (e.g., a
long-acting b2-agonist [LABA]) via a web survey to
measure patient preferences for attributes of COPD phar-
maceutical treatment. A web-based platform for the survey
was selected to maximize recruitment and study sample.
Screening questions were used to determine eligibility of
panelists who responded to the email invitation. Informed
consent via YouGov (Palo Alto, CA, USA) was obtained
prior to web survey completion. Participants completed the
DCE questionnaire, which included screening, sociode-
mographic and clinical questions, a respiratory symptoms
scale, instructions on how to complete DCE items, a
description of the COPD attributes, and the choice tasks.
The choice tasks contained 20 hypothetical scenarios
composed of different levels of different attributes.
2.2.1 Study Population
The PollingPoint panel is a proprietary opt-in internet
survey panel comprising 1.2 million US residents who
participate in YouGov’s web surveys. The study goal was
to recruit approximately 500 US participants with COPD
(or chronic bronchitis and/or emphysema) through the
panel database. The recruitment sample comprised US
participants who self-reported a physician diagnosis of
COPD, met the pre-screening criteria, and had previously
completed YouGov surveys in English. In order to obtain
approximately 500 completed surveys, YouGov issued
email invitations to a pool of approximately 5,130 pro-
spective panel participants in their database who (1) had
previously reported having been diagnosed with COPD; (2)
were 40 years or older, and (3) were current or former
smokers.
A series of screening and eligibility questions deter-
mined eligibility once a potential participant responded to
the email invitation. A flow diagram describing eligible
participants is included in Fig. 1. Participants were eligible
if they (1) were 40 years of age or older; (2) were a current
or previous smoker with at least a 10-pack/year history
(equivalent to one pack or 20 cigarettes per day for at least
10 years); (3) had been diagnosed with COPD (or chronic
bronchitis and/or emphysema) by a clinician or healthcare
provider; (4) were currently on a long-acting maintenance
COPD therapy that included ADVAIR (fluticasone and
salmeterol) and/or SYMBICORT (budesonide and for-
moterol); (5) were able to read and understand English; and
(6) were willing and able to provide informed consent on
the web link in the email invitation. There were no
exclusion criteria with regard to use of short-acting/rescue
medications. If confirmed eligible based on inclusion/
exclusion criteria on the screening form, participants
were directed to a YouGov HIPAA (Health Insurance
Portability and Accountability Act)-compliant Internet
portal. Respondents were provided with a consent state-
ment, and those who agreed to participate were asked to
complete the online survey.
2.2.2 Patient Characteristics
Basic sociodemographic characteristics of interest col-
lected included age, gender, race/ethnicity, employment
status, education, living/domestic situation, and marital
status. COPD and clinical characteristics collected included
smoking history, diagnosis, disease duration, disease
severity, use of maintenance and rescue medicines, overall
health, and comorbid health conditions. The Breathless-
ness, Cough, and Sputum Scale (BCSS) was also admin-
istered; BCSS was developed as a three-item patient-
reported instrument for tracking the severity of respiratory
symptoms among patients with COPD [27]. Each COPD
symptom (breathlessness, cough, sputum) is rated on a five-
point Likert-type scale ranging from 0 to 4, where higher
responses indicate more severity. Total BCSS scores range
from 0 to 12, where higher scores indicate more overall
severe symptoms for the current day.
2.2.3 DCE Questionnaire
The six study attributes assessed were symptom relief,
speed of feeling the medication begin to work, side effects
of medication, use of rescue (quick-relief) medication, ease
of inhaler use, and monthly co-pay cost. The DCE ques-
tionnaire was composed of two medications with different
levels for each of the six COPD medication attributes.
Instructions were presented prior to the DCE questionnaire
and described COPD and its usual symptoms, and
explained the difference between maintenance and rescue
(quick-relief) medicines that are used to treat COPD (or
chronic bronchitis and/or emphysema). Each of the medi-
cation features was described, and the three levels for each
attribute were detailed.
The complete set of COPD medication attributes and
levels are presented in Table 1. Attribute levels ranged
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from best case to worst case. The symptom attribute
mimics medication effectiveness, ranging from minimal
to maximal relief. Levels for feeling the medication
working were based on clinical reports and focus groups:
some participants reported feeling their medication start
to work quickly; others discussed adapting their morning
routines to take medication well before they were ready to
get up for the day so that the medication would be
working when they needed it. Ease of use of an inhaler
was based on literature noting that important features
were ‘quick to use’ and ‘overall ease of use’ [15]. Levels
for frequency of rescue medication use were set based on
patients reporting hardly any use to daily need during the
focus group discussions; this was also confirmed through
clinical data gathered in this study. Rather than exploring
specific side effects, the discussions focused on whether
the side effects interfered with taking medication, and a
continuum was provided from no side effects to side
effects severe enough to affect whether to take a medi-
cation. Finally, the cost attribute reflects co-pay costs
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based on standard generic and formulary tiers used by
prescription insurance plans.
A balanced overlap design was used to create four
versions of the DCE questionnaire, each of which included
20 choice tasks. Given that the attributes of symptom relief
and the need to use rescue (quick-relief) medication are
related, two prohibitions were built into the design used to
randomly generate the medication choice tasks. The
symptom relief attribute ‘Complete relief’ (level 3) was not
allowed to appear in combination with either ‘3–5 times
per week’ (level 2) or ‘every day’ (level 3) with the use of
rescue (quick-relief) medicine attribute in any medication
profile. Participants were randomly assigned to complete
one of the four versions; the sample size of 500 was large
enough to allow for over 100 participants to complete each
separate version of the DCE questionnaire, thereby
expanding the number and variety of scenarios that could
be presented and reducing individual participant burden.
The DCE questionnaire included instructions, a
description of the attributes, and the medication choice
tasks. In each task, participants were asked to review the
two medications in each scenario and indicate which
medication they would prefer (Medicine A or Medicine B;
a sample task is presented in Fig. 2 as an example). Each of
the tasks was presented as a forced choice question, where
the participant had to indicate which of the two medica-
tions they would prefer (e.g., one scenario might present a
medication that costs $50 per month and have a 5-min
onset, whereas another medication might cost $10 per
month and have a 30-min onset). The participant would
choose which scenario (or drug type) they preferred. The
forced choice nature of the task provided help in under-
standing how participants make trade-offs between attri-
butes when making their medication selections.
Two fixed tasks with a clear preference were included in
each questionnaire version as consistency checks to ensure
that participants correctly understood how to complete the
choice tasks. Each fixed task included a highly favorable
medicine (complete relief, works within 5 min, quick and
easy to use, rarely need to use rescue inhaler, no side
effects/mild side effects, and $5 per month) that should
have been chosen as the preferred medicine; failure to
choose the preferred medicine could indicate that instruc-
tions on how to complete the choice tasks were not
understood correctly.
2.2.4 Statistical Analyses
All data were collected in adherence with the study pro-
tocol and in accordance with good clinical research
Table 1 Chronic obstructive
pulmonary disease maintenance
medicine attributes and levels
Attribute 1: How well the maintenance medicine relieve symptoms
Level 1: Little or no relief of symptoms after taking the maintenance medicine
Level 2: Some relief of symptoms after taking the maintenance medicine
Level 3: Complete relief of symptoms after taking the maintenance medicine
Attribute 2: How quickly you feel the maintenance medicine start to work
Level 1: Feel maintenance medicine begin to work within 5 min of taking it
Level 2: Feel maintenance medicine begin to work within 20 min of taking it
Level 3: Feel maintenance medicine begin to work within 30 min or more of taking it
Attribute 3: How easy it is to use your inhaler device
Level 1: Inhaler is quick and easy to use
Level 2: Inhaler requires some practice and care to use
Level 3: Inhaler is more difficult and time-consuming to use
Attribute 4: Rescue (quick-relief) medicine use
Level 1: Rarely need to use rescue (quick-relief) inhaler, 1–2 times per week or less
Level 2: Need to use rescue (quick-relief) inhaler 3–5 times per week
Level 3: Need to use rescue (quick-relief) inhaler every day
Attribute 5: Side effects of maintenance medicine
Level 1: No side effects
Level 2: Mild side effects, but they do not interfere with taking the medicine
Level 3: Moderate to severe side effects that may stop you from taking the medicine
Attribute 6: Out-of-pocket cost of maintenance medicine
Level 1: $5 per month
Level 2: $25 per month
Level 3: $50 per month
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practice. Sawtooth Software version 6.6 (Sawtooth Soft-
ware Inc., Sequim, WA, USA) and SAS statistical software
version 9.1 (SAS Institute Inc., Cary, NC, USA) were used
to conduct the analyses. Missing data were handled per the
instrument developer scoring instructions for the BCSS. No
other imputation for missing data was performed; the DCE
analysis does not allow for any data imputation.
Frequencies for participant disposition are reported for
invitees (individuals issued an email invitation), responders
(individuals who responded by opting in to the web link in
the email invitations), eligible participants (individuals
who responded and were eligible to complete the survey
according to the inclusion/exclusion criteria), and compl-
eters (eligible participants who completed the web survey
in its entirety with 10 % or less missing responses).
Descriptive statistics for participant-reported sociodemo-
graphic and clinical questions, including the BCSS, are
reported for the total sample. Categorical variables are
summarized by frequency statistics, and continuous vari-
ables report mean, standard deviation (SD), and minimum/
maximum.
Participant preference for COPD attributes was evalu-
ated based on data from the DCE questionnaire. Compre-
hension of choice tasks was evaluated by examining
response frequencies for consistency check questions and
average utilities for participants with consistent and
inconsistent response patterns. Utility scores were deter-
mined for each level of the COPD attributes as average
zero-centered differences from a main-effects model. The
utilities or preference weights reflect strength of participant
preference for each of the COPD attributes. WTP was
determined for each attribute level by assigning currency
values to the utility (preference) scores. These values
represent an estimate of the relative monetary value of
obtaining improvements in the level of a COPD attribute.
Multinomial logistic regression methods were used to
estimate group-level preference values for each attribute
level and the effect size of each attribute’s levels. The
marginal effects of each attribute’s levels was divided by
the marginal effect from a dollar change in co-pay amount
to represent the participant’s marginal WTP for improve-
ments within each COPD attribute, as measured in dollars
of co-pay per month. Marginal effects and marginal WTP
(to avoid the level) are presented for each attribute level.
The reference level is the lowest (most favorable) level for
each of the COPD attributes. WTP estimates of subgroups
were also assessed for COPD severity level, age, and
gender.
3 Results
3.1 Phase I: Qualitative Results
Slightly over one-half of the focus group participants
(N = 13) were female (n = 7), and most were White
(84.6 %), with a mean age of 70 years (SD 5.4). Patients
had an overall disease severity of moderate (Global Ini-
tiative for COPD [GOLD]-2; 38.5 %) or severe COPD
(GOLD-3; 61.5 %) and had been diagnosed with COPD for
Fig. 2 Example of discrete choice experiment choice task
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an average of 3.5 (SD 1.8) years. All were receiving a
combination LABA ? glucocorticosteroid inhaler, and the
majority (92.3 %) also used an inhaled b2-agonist short
acting/rescue medication.
Qualitative analysis of the focus group data involved the
identification of themes based upon review of the tran-
scripts. Important aspects of COPD and maintenance
medications identified by patients included symptoms,
medication efficacy/symptom relief, speed with which
patients felt their medication working/onset of medication
action, rescue inhaler/reliever use, comfort with delivery
system/mode of administration, and side effects/adverse
effects.
Study participants experienced typical COPD symp-
toms, including shortness of breath, chest tightness, cough,
phlegm/mucus, fatigue, and wheezing, which tended to
worsen upon exertion. The prevailing symptom experi-
enced by patients was shortness of breath, described as
‘‘loss of breath,’’ ‘‘can’t get air,’’ and ‘‘takes your breath
away.’’ Some patients described having more difficulty
with symptoms at certain times of the day (e.g., morning)
or times of the year (e.g., cold or humid weather, spring,
certain months). Patients were very concerned with how
well their maintenance medication worked. When
describing their medication, comments such as ‘‘helping
(them) to breathe,’’ ‘‘improving breathing,’’ ‘‘breathing
without strain,’’ ‘‘feeling the medication open up/clear their
lungs,’’ and ‘‘being able to go a longer time’’ were evi-
dence to patients that the medication was working. How
quickly their COPD maintenance medication worked was
instrumental. Fast speed of action was described as
allowing them ‘‘to start moving around’’ and ‘‘feeling
better as soon as (they) took their medication.’’ Rescue
medications were relied on by patients because they knew
that they could take it immediately if their symptoms
flared, and that it provided immediate relief that they could
feel.
Ease of use in administering COPD maintenance med-
ications was also important. For example, patients descri-
bed difficulty with inserting a capsule into their delivery
device and noted that medication with a metered dose was
convenient and easy to use. Patients also cited preference
for pill or aerosol spray form (similar to a rescue inhaler),
as inhaling a dry powder medication could be difficult
when they were experiencing shortness of breath. Patients
were also concerned with side effects related to using
COPD medication, and noted experiencing dizziness/
lightheadedness, vision problems, leg cramping, and throat
hoarseness, and discussed concerns about glaucoma and
cataract risk. It should be noted that frequency of dosing
was not a major issue for the patients, nor was cost, as
study participants had prescription drug insurance
coverage.
Results from a brief review of recent literature and qual-
itative research conducted with patients in phase I were used
to develop the attributes that were evaluated in phase II of the
study. The key concepts/themes related to COPD and its
treatment identified in qualitative data analysis of focus
group transcripts formed the basis of COPD maintenance
medication attributes and levels used in the DCE study.
3.2 Phase II: DCE Results
3.2.1 Participant Disposition
YouGov issued email invitations to 5,130 enrollees who
met the criteria for previous diagnosis of COPD. Of these,
57 % (n = 2,930) responded (Fig. 3). A total of 76 %
(n = 2,234) of responders were ineligible for the survey;
24 % (n = 696) were eligible based on screening criteria,
and the majority of these (n = 515; 74 %) completed the
survey. The study sample is made up of 515 participants
who completed the survey.
3.2.2 Participant Characteristics
Slightly over one-half of survey participants were female,
and the majority were White, with a mean age of 62 years
(SD 9.99) (Table 2). Most were former smokers, and
almost all had smoked for more than 10 years (Table 2).
The time from diagnosis for COPD ranged from 2 to
10 years (Table 2). Almost one-half characterized them-
selves as having moderate COPD, with fewer reporting
severe or very severe COPD. Most subjects reported using
fluticasone/salmeterol as their maintenance medication and
albuterol for rescue (Table 2). Almost one-quarter of
respondents (24 %) reported using rescue medication less
than once a week, while another one-quarter reported
needing to use a rescue medication from one to five times a
week. Nearly 15 % reported using rescue medications
more than ten times per week.
Over one-half (58 %) of participants felt that their overall
health was either fair or poor. Most participants reported
having at least one comorbid health condition. The mean
total BCSS score was 4.5 (SD 2.42) on the day of survey
completion; for individual COPD symptoms, patients on
average reported moderate breathing difficulty (mean 2.1,
SD 1.09), rare/occasional cough (mean 1.5, SD 1.03), and
mild trouble with sputum (mean 1.0, SD 0.94).
3.2.3 Evaluation of DCE Task Comprehension
Task comprehension was evaluated using two consistency
check questions (items 1 and 8). Out of the total sample of
515 participants, 441 (86 %) chose the preferred medicine
for both consistency check questions, and 496 (96 %) chose
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the preferred medicine for at least one of the two consis-
tency check questions. Utility (preference) scores were
generated for the total sample, as well as for the two sub-
samples based on participant responses to consistency
check questions (data not shown). The same pattern of
average utilities scores was generated using the total sam-
ple, as well as the two subsets of participants. These results
suggested that unexpected responses to the consistency
check questions did not produce substantially different
results. In addition, no significant differences in sociode-
mographic characteristics were detected, with the excep-
tion that those with inconsistent responses tended to report
having slightly more severe COPD than those with con-
sistent responses. Therefore, subsequent analyses were
conducted using all 515 participants.
3.2.4 Utility (Preference) Scores
The best or most favorable level was consistently preferred
for each separate COPD medication attribute over the other
less favorable levels. There was a logical ordering of utilities
for the three levels presented for each COPD attribute (data
not shown); for example, ‘complete relief’ had a higher
preference score than ‘some relief,’ which in turn had a
higher preference score than ‘little or no relief’ for the
symptom relief attribute. Each COPD medication attribute
(symptom relief, feeling maintenance medication begin to
work, ease of use, rescue medicine use, side effects, and out-
of-pocket cost) was independently important to participants.
3.2.5 Willingness to Pay (WTP)
WTP estimates were generated to assign monetary values
(in monthly out-of-pocket co-pay dollars) to each COPD
attribute level. This analysis evaluated whether participants
would theoretically pay a premium to obtain each of the
COPD maintenance medication attributes. The WTP ana-
lysis confirmed that participants found all of the attributes
to be desirable elements in a COPD maintenance medica-
tion. Results indicated that participants were willing to pay
a premium for better results from a maintenance medica-
tion (Table 3). Within each attribute, WTP estimates
revealed that participants would pay to obtain the best
(most favorable) level for each attribute, compared with the
worst level. WTP estimates based on monthly co-pay
dollars were $US64 for complete relief of symptoms,
$US59 to have no side effects, $US32 to rarely use rescue
medication, $US16 for an inhaler that is quick and easy to
use, and $US13 for feeling medication work within 5 min,
for the best (most favorable) level compared with the worst
(least favorable) level for each attribute.
WTP varied with the level of COPD disease severity
(Table 4). Participants who reported severe COPD (i.e.,
severe or very severe COPD) were willing to pay more per
month to obtain favorable COPD medication attributes
than were those classifying themselves as having mild or
moderate COPD for some attributes, particularly for
symptom relief and feeling medication start to work
quickly. Those reporting mild COPD were willing to pay
more for less frequent need to use rescue medicines. WTP
estimates across COPD severity levels ranged from $US62
to 68 for complete relief of symptoms, $US58 to 61 to have
no side effects, $US25 to 36 to rarely use rescue medica-
tion, $US12 to 19 for an inhaler that is quick and easy to
use, and $US10 to 18 to feel medication work within
5 min, compared with the worst level for each attribute.
Participants ranged from 40–88 years old, and WTP
was evaluated by age groups (Table 5). WTP was
Fig. 3 Survey participant
disposition. DCE discrete
choice experiment
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estimated separately for two age groups; participants
aged 40–62 years (n = 249) and participants aged
63–88 years (n = 266), based on a mean split. Older
participants had higher WTP for virtually all COPD
medication attributes than younger participants. WTP
estimates in monthly co-pay dollars ranged from $US52
to 78 for complete relief of symptoms, $US48 to 71 to
have no side effects, $US28 to 35 to rarely use rescue
medication, $US13 to 18 for an inhaler that is quick and
easy to use, and $US11 to 16 to feel medication work
within 5 min, compared with the worst level for each
attribute. WTP across attributes ranged from $US16 to
78 for participants aged 63–88 years and $US11 to 52
for participants aged 40–62 years.
WTP was examined by gender of the participant with
COPD (Table 6). COPD disease severity was similar by
gender; almost half of men and women reported having
moderate COPD. Men with COPD had higher WTP for
complete symptom relief ($US70 vs. 59), quick and easy
to use inhaler ($US19 vs. 13), less frequent need to use
rescue medicine ($US35 vs. 29), and avoiding side
effects ($US68 vs. 52) compared with women. However,
women were willing to pay more monthly than men for
a medicine that they can feel begin to work quickly
($US14 vs. 11). WTP estimates ranged from $US59 to
Table 2 Discrete choice experiment participant-reported sociode-
mographic and clinical characteristics (N = 515)
Characteristics Total (N = 515)
Age in yearsa, mean (SD) [range] 62.3 (9.99) [40–88]
Men, n (%) 230 (44.66 %)
Employment status, n (%)
Employed, full-time, or part-time 94 (18.25 %)
Retired 220 (42.72 %)
Disabled 154 (29.90 %)
Other 47 (9.13 %)
Highest level of education, n (%)
Elementary/primary school 2 (0.39 %)
Secondary/high school 136 (26.41 %)
Some college 202 (39.22 %)
College degree or more 162 (31.46 %)
Other 13 (2.52 %)
Racial backgroundb, n (%)
White 490 (95.15 %)
Black or African American 10 (1.94 %)
Asian 1 (0.19 %)
American Indian or Alaska Native 14 (2.72 %)
Other 12 (2.33 %)
Hispanic or Latino, n (%) 10 (1.94 %)
Marital status, n (%)
Married 280 (54.37 %)
Divorced 112 (21.75 %)
Never married/single 22 (4.27 %)
Widowed 65 (12.62 %)
Other 36 (6.99 %)
Smoking statusc, n (%)
Current smoker 178 (34.56 %)
Former smoker 337 (65.44 %)
Typical amount smokedc, n (%)
1 pack/day 185 (35.92 %)
1 packs/day 140 (27.18 %)
2 packs/day 101 (19.61 %)
2 packs/day 48 (9.32 %)
C3 packs/day 41 (7.96 %)
COPD disease duration, n (%)
\1 year 23 (4.47 %)
1 to \2 years 54 (10.49 %)
2 to \5 years 182 (35.34 %)
5–10 years 161 (31.26 %)
[10 years 94 (18.25 %)
Don’t know 1 (0.19 %)
Participant-reported COPD disease severity, n (%)
Mild 108 (20.97 %)
Moderate 238 (46.21 %)
Severe 121 (23.50 %)
Very severe 39 (7.57 %)
Don’t know 9 (1.75 %)
Table 2 continued
Characteristics Total (N = 515)
Current maintenance medication for COPDc, n (%)






Both (ADVAIR and SYMBICORT) 28 (5.44 %)




Levalbuterol (e.g., XOPENEX) 30 (5.83 %)
Other 64 (12.43 %)
Do not use rescue (quick-relief) medicine 100 (19.42 %)
COPD chronic obstructive pulmonary disease, SD standard deviation
a Date of birth was asked in participant eligibility screening. Age was
computed using participated-reported date of birth
b Participants may report more than one category; racial background
may not be mutually exclusive
c Questions about smoking history and current maintenance medicine
were asked in eligibility screening
d Participants may report more than one category; rescue medications
may not be mutually exclusive
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70 for complete relief of symptoms, $US52 to 68 to
have no side effects, $US29 to 35 to rarely use rescue
medication, $US13 to 19 for an inhaler that is quick and
easy to use, and $US11 to 14 to feel medication work
within 5 min, compared with the worst level for each
attribute.
Table 3 Willingness to pay for chronic obstructive pulmonary disease attributes (N = 515)
Attributes and levels Marginal effect (95 % CI) Marginal WTP to avoid level (95 % CI)
Relieves symptoms (reference: complete relief)
Little or no relief -1.23 (-1.33, -1.12) $63.62 (58.16–69.08)
Some relief -0.54 (-0.64, -0.43) $27.74 (22.28–33.20)
Feel medicine start to work (reference: within 5 min)
Within 20 min -0.19 (-0.24, -0.15) $10.00 (7.74–12.27)
Within 30 min or more -0.25 (-0.30, -0.21) $13.02 (10.75–15.28)
Ease of use (reference: quick and easy)
Requires some practice and care -0.09 (-0.14, -0.04) $4.75 (2.25–7.25)
More difficult and time-consuming -0.30 (-0.35, -0.25) $15.53 (13.03–18.03)
Rescue medicine use (reference: rarely, 1–2 times per week or less)
3–5 times per week -0.38 (-0.48, -0.29) $19.83 (14.99–24.67)
Every day -0.61 (-0.70, -0.52) $31.57 (26.73–36.41)
Side effects (reference: no side effects)
Mild side effects -0.29 (-0.33, -0.24) $14.81 (12.40–17.22)
Moderate to severe side effects -1.13 (-1.18, -1.09) $58.69 (56.28–61.11)
Reference was the most favorable level for each COPD medication attribute. 95 % CIs that did not include zero were considered to be
statistically significant
CI confidence interval, COPD chronic obstructive pulmonary disease, WTP willingness to pay
Table 4 Willingness to pay estimates for chronic obstructive pulmonary disease attributes by disease severity (N = 506)
Attributes and levels Marginal WTP to avoid level by COPD disease severitya (95 % CI)
Mild (N = 108) Moderate (N = 238) Severe/very severe (N = 160)
Relieves symptoms (reference: complete relief)
Little or no relief $61.97 (51.21–72.74) $65.54 (57.52–73.56) $67.51 (56.31–78.71)
Some relief $30.51 (19.74–41.27) $29.36 (21.34–37.38) $26.64 (15.44–37.83)
Feel medicine start to work (reference: within 5 min)
Within 20 min $5.48 (0.92–10.04) $10.42 (7.17–13.68) $13.41 (8.72–18.10)
Within 30 min or more $10.43 (5.87–15.00) $10.04 (6.79–13.29) $18.33 (13.64–23.02)
Ease of use (reference: quick and easy)
Requires some practice and care $8.70 (3.55–13.86) $6.08 (2.52–9.63) -$0.19 (-$5.40–5.02)
More difficult and time-consuming $11.88 (6.72–17.04) $19.20 (15.65–22.76) $12.81 (7.60–18.01)
Rescue medicine use (reference: rarely, 1–2 times per week or less)
3–5 times per week $20.50 (11.15–29.86) $19.98 (12.88–27.07) $18.13 (8.10–28.16)
Every day $36.02 (26.67–45.38) $33.68 (26.58–40.78) $24.54 (14.51–34.56)
Side effects (reference: no side effects)
Mild side effects $19.41 (14.45–24.38) $13.46 (9.97–16.95) $13.46 (8.57–18.35)
Moderate to severe side effects $61.03 (56.07–66.00) $57.77 (54.28–61.26) $60.35 (55.46–65.24)
Reference was the most favorable level for each COPD medication attribute. 95 % CIs that did not include zero were considered to be
statistically significant. Negative marginal WTP value for ‘Ease of use’ was due to a relatively small difference in preference between attribute
levels ‘Quick and easy’ and ‘Requires some practice and care’
CI confidence interval, COPD chronic obstructive pulmonary disease, WTP willingness to pay
a COPD disease severity was participant-reported (Mild, Moderate, Severe, Very severe, Don’t know). Nine participants with response ‘Don’t
know’ were excluded
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4 Discussion
This study identified and evaluated the importance of
maintenance medication attributes to COPD patients.
Based on findings from focus group discussions, attributes
of COPD maintenance medication important to patients
included symptom relief, speed with which patients felt
their medication working, use of rescue medicine, ease of
use for inhaler, presence of side effects, and out-of-pocket
co-pay cost. Each attribute was associated with a value in
Table 5 Willingness to pay estimates for chronic obstructive pulmonary disease attributes by age group (N = 515)
Attributes and levels Marginal WTP to avoid level by age group (95 % CI)
40–62 years old (N = 249) 63–88 years old (N = 266)
Relieves symptoms (reference: complete relief)
Little or no relief $51.59 (44.41–58.77) $77.88 (69.51–86.24)
Some relief $20.49 (13.31–27.67) $36.41 (28.05–44.78)
Feel medicine start to work (reference: within 5 min)
Within 20 min $8.28 (5.28–11.28) $11.97 (8.53–15.41)
Within 30 min or more $10.51 (7.51–13.51) $15.95 (12.51–19.39)
Ease of use (reference: quick and easy)
Requires some practice and care $4.46 (1.15–7.76) $5.27 (1.46–9.07)
More difficult and time-consuming $13.48 (10.17–16.78) $18.07 (14.27–21.88)
Rescue medicine use (reference: rarely, 1–2 times per week or less)
3–5 times per week $19.71 (13.27–26.14) $19.53 (12.21–26.85)
Every day $28.41 (21.98–34.84) $35.16 (27.84–42.48)
Side effects (reference: no side effects)
Mild side effects $13.23 (10.11–16.35) $17.00 (13.25–20.75)
Moderate to severe side effects $48.29 (45.17–51.41) $71.01 (67.26–74.76)
Reference was the most favorable level for each COPD medication attribute. 95 % CIs that did not include zero were considered to be
statistically significant
CI confidence interval, COPD chronic obstructive pulmonary disease, WTP willingness to pay
Table 6 Willingness to pay estimates for chronic obstructive pulmonary disease attributes by gender (N = 515)
Attributes and levels Marginal WTP to avoid level by gender (95 % CI)
Male (N = 230) Female (N = 285)
Relieves symptoms (reference: complete relief)
Little or no relief $69.71 (60.62–78.80) $59.10 (52.34–65.86)
Some relief $27.30 (18.21–36.38) $27.58 (20.83–34.34)
Feel medicine start to work (reference: within 5 min)
Within 20 min $10.36 (6.63–14.09) $9.72 (6.89–12.54)
Within 30 min or more $11.45 (7.72–15.18) $14.12 (11.29–16.94)
Ease of use (reference: quick and easy)
Requires some practice and care $8.00 (3.78–12.22) $2.58 (-0.48–5.64)
More difficult and time-consuming $18.57 (14.35–22.79) $13.32 (10.25–16.38)
Rescue medicine use (reference: rarely, 1–2 times per week or less)
3–5 times per week $23.29 (15.23–31.34) $17.86 (11.87–23.85)
Every day $35.23 (27.18–43.29) $29.29 (23.30–35.27)
Side effects (reference: no side effects)
Mild side effects $12.99 (8.97–17.01) $15.92 (12.95–18.90)
Moderate to severe side effects $67.57 (63.55–71.59) $52.44 (49.47–55.42)
Reference was the most favorable level for each COPD medication attribute. 95 % CIs that did not include zero were considered to be
statistically significant
CI confidence interval, COPD chronic obstructive pulmonary disease, WTP willingness to pay
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co-pay dollars ranging from $US5 to 78, indicating that
subjects would theoretically pay to obtain the benefit of a
drug that had these attributes. These findings suggest that
patients making individual health choices expressed WTP
more out-of-pocket for a COPD maintenance medication
with desirable features. Efficacy and side effects are often
of primary concern for patients, and, as expected, symptom
relief and avoiding side effects were highly valued, with
higher WTP estimates for an efficacious medication with
low risk. However, additional attributes, such as being able
to feel the medicine begin to work quickly, inhaler ease of
use, and the need to use rescue medicine were also asso-
ciated with non-negligible WTP estimates, suggesting that
these attributes are important considerations when evalu-
ating a medication and are clearly meaningful to
participants.
It should be noted that participants consistently pre-
ferred the best level for each individual COPD medication
attribute on two consistency check questions embedded in
each version of the DCE questionnaire, thus providing
confidence in patient responses. Consistency in responses
also helped to confirm that COPD medication attributes
and levels derived from qualitative background research
were appropriate.
Some differences were found in WTP when results were
examined by COPD severity level. Patients with COPD
classified as severe or very severe were willing to pay more
for symptom relief and feeling the medication begin to
work quickly. This may be due to a heightened awareness
of symptoms and their impact among those with more
severe disease. Severe patients were willing to pay almost
$US8 more than less severe patients in order to obtain a
medication they could feel working within 5 min. Inter-
estingly, less frequent rescue medication use was not as
important to patients with severe illness compared with
those with less severe COPD. While older patients dem-
onstrated higher WTP than younger patients, factors other
than age may have contributed to this finding; confounding
factors could include duration and severity of illness, in
light of the progressive nature of COPD, and income and
access to care for older patients. Additional research would
be needed to further explore the relationship between age
and WTP in COPD.
There are several limitations in this study. A limitation
of the qualitative phase was that the background research
conducted was solely focused on obtaining information
about COPD medication delivery. A formal, systematic,
and comprehensive review of all COPD literature was not
conducted; rather, a brief, targeted review of recent liter-
ature (2000–2008) was performed that focused on COPD
treatment/medication characteristics. Only two focus
groups were conducted with COPD patients, and these
groups also concentrated on COPD medication delivery as
the main topic of discussion; there was limited inquiry into
other aspects of the patient experience with COPD or other
COPD treatments.
In the quantitative phase, medication scenarios posed to
patients were hypothetical, and WTP in monthly co-pay
dollars derived from preference weights; these stated
preferences may differ from the actual choices that patients
would make in a real-world setting. In addition, unmodeled
heterogeneity in medication preferences across respondents
may introduce bias and impact study findings. All survey
data were based on respondent self-report; no physician
records or diagnostic information were accessed. Partici-
pants self-reported both the diagnosis of COPD, as well as
their severity level, and their perceptions may differ from
information that would have been obtained from clinical
sources. In addition, although minimum inclusion criteria
were required, no exclusion criteria were specified for the
study and participants were self-excluded by not selecting
to participate in the survey. Based on the inclusion criteria
that were used, patients could have had other comorbid
health conditions present, which may have affected their
responses. Data on household income, health plan cover-
age, and co-pay levels were not collected, so the impact of
these factors as covariates for WTP could not be evaluated.
Respondents were not asked after completing the choice
tasks to rank-order the six medication attributes in their
opinion from most to least important to solicit their direct
preference; this additional information about their per-
ceived ranking order, in addition to the indirect ranking
generated by the preference utility analysis, would have
been informative had it been collected.
Both phases of the study involved COPD patients in the
USA who were largely treated with LABA or long-acting
muscarinic antagonist (LAMA) therapies; this may limit
the generalizability of these results to the larger population
of COPD patients, as well as patients in other countries
with different healthcare systems and approaches to ther-
apy. However, the findings obtained in this study improve
our understanding of factors that may contribute to patient
preference for maintenance medications and potential areas
for future research on patient beliefs and perceptions about
medication that may subsequently help to improve
adherence.
5 Conclusions
This study of US patients showed that patients take into
consideration multiple attributes of a COPD maintenance
therapy, and that, in hypothetical scenarios, patients
expressed WTP more for a medication with attractive char-
acteristics. Attributes such as decreased use of rescue med-
ication, ease of use for inhaler, and being able to feel a
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medication begin to work quickly are aspects beyond safety
and efficacy that patients consider in evaluating preference
for a COPD maintenance medication. A medication that
possesses an attribute that is particularly attractive or one that
another medication lacks may also distinguish itself from
other similar therapies and potentially provide added value
from the patient perspective. Patients may also be more
likely to adhere to a medication that they perceive to have
attractive characteristics and valuable benefits. Findings in
this study identified multiple concepts relevant to patient
preference for maintenance medication in the context of
hypothetical scenarios; additional research evaluating
patient preference for specific medications with similar
properties and in other countries/healthcare systems would
be helpful to further evaluate this in a real-world setting.
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